SHYFT Analytics, a Medidata Solutions company, and PAREXEL International, have entered into a strategic partnership that establishes SHYFT’s technology as an integral part of PAREXEL’s foundation for Real-World Evidence (RWE) generation and outcomes research for biopharmaceutical and medical device clients.
 
The collaboration combines PAREXEL’s scientific and clinical services with SHYFT’s suite of RWE products to help provide insights and outcomes from patient-level data more efficiently to customers worldwide. The pairing aims to optimize the design and execution of ongoing and retrospective clinical studies, from late-phase research to safety studies to the support of pragmatic clinical trials.
 
According to the company, SHYFT’s QUANTUM Real-World Evidence platform allows researchers to generate robust “submission-ready” studies 92% faster than industry standard, on average. PAREXEL will be leveraging the SHYFT platform to perform at-scale analyses including cohort modeling, trial feasibility assessment, and large scale observational studies.
 
“PAREXEL is, and always has been, committed to helping sponsor organizations navigate the complexities of drug development,” said Michelle Hoiseth, chief data officer for PAREXEL. “The growing availability of real-world data combined with innovative analytics methods and groundbreaking technologies present an opportunity to assist our organization in delivering on that commitment. As we have evaluated capabilities in this area, we have found SHYFT’s platform to be unmatched among other RWE platforms, in its ability to provide answers to complex scientific and commercial queries quickly, with repeatable precision, in a user-friendly manner. By leveraging SHYFT’s platform, our teams will be able to generate real-time insights spanning strategic consulting to pivotal trial feasibility to late-phase health economics and outcomes research (HEOR) analytics with a much higher level of efficiency. This, combined with our enhanced data linking capabilities, is a significant step forward in our approach to help sponsors leverage real-world data in a meaningful way now and in the future.”